Literature DB >> 21109947

TRAIL-induced caspase/p38 activation is responsible for the increased catalytic and invasive activities of Akt.

Bo K Sun1, Joo-Hang Kim, Hoan N Nguyen, So Y Kim, Seeun Oh, Yong J Lee, Jae J Song.   

Abstract

We previously observed that TRAIL induces acquired TRAIL resistance coinciding with increased Akt phosphorylation brought about by the Src-PI3K-Akt signaling pathways and mediated by c-Cbl. c-Cbl, a ubiquitously expressed cytoplasmic adaptor protein, is simultaneously involved in the rapid degradation of TRAIL receptors and Akt phosphorylation during TRAIL treatment. Here, we show that Akt phosphorylation is not exclusively responsible for acquired TRAIL resistance. Akt catalytic activation is known to increase during metabolic oxidative stress, but we show that TRAIL also dramatically induces the catalytic activation of Akt in TRAIL-sensitive cells, but not in TRAIL-resistant cells. This suggests that Akt catalytic activation during TRAIL-induced apoptosis is likely to play a compensatory role in the maintenance of cell homeostasis. In addition, activated p38 and phosphorylated HSP27 were found to act as downstream effector molecules of p38 during TRAIL treatment and were shown to be responsible for increased Akt catalytic and invasive activities.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21109947      PMCID: PMC3004145     

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  50 in total

Review 1.  Diverse functions of JNK signaling and c-Jun in stress response and apoptosis.

Authors:  S Leppä; D Bohmann
Journal:  Oncogene       Date:  1999-11-01       Impact factor: 9.867

2.  Evidence for two modes of development of acquired tumor necrosis factor-related apoptosis-inducing ligand resistance. Involvement of Bcl-xL.

Authors:  Jae J Song; Jee Young An; Yong Tae Kwon; Yong J Lee
Journal:  J Biol Chem       Date:  2006-11-15       Impact factor: 5.157

3.  TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma.

Authors:  A Trauzold; D Siegmund; B Schniewind; B Sipos; J Egberts; D Zorenkov; D Emme; C Röder; H Kalthoff; H Wajant
Journal:  Oncogene       Date:  2006-06-05       Impact factor: 9.867

Review 4.  p38 MAPK in development and cancer.

Authors:  Cynthia Bradham; David R McClay
Journal:  Cell Cycle       Date:  2006-04-17       Impact factor: 4.534

5.  Opposing roles for ERK1/2 in neuronal oxidative toxicity: distinct mechanisms of ERK1/2 action at early versus late phases of oxidative stress.

Authors:  Yue Luo; Donald B DeFranco
Journal:  J Biol Chem       Date:  2006-04-18       Impact factor: 5.157

6.  MAPK-activated protein kinase-2 (MK2)-mediated formation and phosphorylation-regulated dissociation of the signal complex consisting of p38, MK2, Akt, and Hsp27.

Authors:  Chunlei Zheng; Ziyang Lin; Zhizhuang Joe Zhao; Yajun Yang; Hanben Niu; Xun Shen
Journal:  J Biol Chem       Date:  2006-10-02       Impact factor: 5.157

7.  P38 MAPK protects against TNF-alpha-provoked apoptosis in LNCaP prostatic cancer cells.

Authors:  M Ricote; I García-Tuñón; B Fraile; C Fernández; P Aller; R Paniagua; M Royuela
Journal:  Apoptosis       Date:  2006-11       Impact factor: 4.677

8.  Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal.

Authors:  M Hetman; J E Cavanaugh; D Kimelman; Z Xia
Journal:  J Neurosci       Date:  2000-04-01       Impact factor: 6.167

9.  Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion.

Authors:  Yi Lu; Zhong Cai; Deborah L Galson; Guozhi Xiao; Yulin Liu; Diane E George; Mona F Melhem; Zhi Yao; Jian Zhang
Journal:  Prostate       Date:  2006-09-01       Impact factor: 4.104

10.  MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer.

Authors:  L Xu; S Chen; R C Bergan
Journal:  Oncogene       Date:  2006-05-18       Impact factor: 9.867

View more
  5 in total

Review 1.  Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family.

Authors:  K Azijli; B Weyhenmeyer; G J Peters; S de Jong; F A E Kruyt
Journal:  Cell Death Differ       Date:  2013-04-12       Impact factor: 15.828

2.  Modeling dynamics of cell-to-cell variability in TRAIL-induced apoptosis explains fractional killing and predicts reversible resistance.

Authors:  François Bertaux; Szymon Stoma; Dirk Drasdo; Gregory Batt
Journal:  PLoS Comput Biol       Date:  2014-10-23       Impact factor: 4.475

3.  From Oxidative Stress Damage to Pathways, Networks, and Autophagy via MicroRNAs.

Authors:  Nikolai Engedal; Eva Žerovnik; Alexander Rudov; Francesco Galli; Fabiola Olivieri; Antonio Domenico Procopio; Maria Rita Rippo; Vladia Monsurrò; Michele Betti; Maria Cristina Albertini
Journal:  Oxid Med Cell Longev       Date:  2018-04-12       Impact factor: 6.543

4.  Cells surviving fractional killing by TRAIL exhibit transient but sustainable resistance and inflammatory phenotypes.

Authors:  Deborah A Flusberg; Jérémie Roux; Sabrina L Spencer; Peter K Sorger
Journal:  Mol Biol Cell       Date:  2013-05-22       Impact factor: 4.138

5.  Depletion of CABYR-a/b sensitizes lung cancer cells to TRAIL-induced apoptosis through YAP/p73-mediated DR5 upregulation.

Authors:  Qianqian Xiao; Zunlei Qian; Weiqing Zhang; Jin Liu; Enze Hu; Jinsan Zhang; Mingying Li; Junhao Wang; Fei Kong; Yunguang Li; Rui Wang; Xiaohua Tan; Dacheng He; Xueyuan Xiao
Journal:  Oncotarget       Date:  2016-02-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.